Actively Recruiting
Azithromycin Compared to Placebo to Reduce Exacerbations in Adults With Non-Cystic Fibrosis Bronchiectasis A Randomized Double-Blind Trial
Led by Assiut University · Updated on 2026-09-24
500
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating azithromycins effect on adults with non-cystic fibrosis bronchiectasis NCFB in the AMBER trial. This phase 4, randomized, double-blind, placebo-controlled study aims to determine if taking azithromycin daily for 12 months, along with standard bronchiectasis care, reduces the chance of experiencing at least one bronchiectasis exacerbation compared to placebo. The study is conducted within the Assiut University bronchiectasis translational research platform and follows a parallel-group design. Participants are randomly assigned in equal groups to receive either 250 mg of azithromycin or a matching placebo once daily for 12 months, both alongside their usual bronchiectasis care. Standard care may include medications like mucolytics and bronchodilators, chest physiotherapy, patient education, airway-clearance support, and treatment for acute exacerbations as needed. The trial uses a concealed randomization method with quadruple masking to keep participants and study staff unaware of treatment assignments during the study. Throughout the 12-month follow-up, participants will undergo clinical, functional, radiological, inflammatory, and safety assessments. Researchers will monitor bronchiectasis exacerbations, lung function FEV1%, oxygen saturation, inflammation markers, symptom scales, and adverse events. The study evaluates both the occurrence and timing of exacerbations, hospitalizations, and changes in health questionnaires. Safety monitoring includes cardiac concerns, gastrointestinal intolerance, and treatment discontinuation. The total participation period is 12 months with planned thorough follow-up visits and assessments.
CONDITIONS
Brief Title
Azithromycin to Modify Bronchiectasis Exacerbation Risk
Research Team
A
Ahmad M Shaddad, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here